CD274 and breast cancer: The IMpassion130 study of the PD-L1 targeting antibody atezolizumab in combination with nab-paclitaxel demonstrated a significant improvement in overall survival in PD-L1 positive TNBC (22.0 vs 15.5 months) indicating the potential clinical impact of exploiting immunotherapies in this subgroup of breast cancer [14].